Most cancer treatments, from traditional radiotherapy to emerging chemodynamic therapies, share a common weapon: the generation of reactive oxygen species (ROS). These volatile molecules cause lethal damage to DNA and lipids, effectively "burning" the cancer cell from the inside out. However, tumors are not passive targets. They survive in high-stress environments by building a robust biochemical shield of antioxidants.
Recent research focuses on a "one-two punch" strategy: generating massive amounts of ROS while simultaneously dismantling the tumor's internal defenses. By understanding the metabolic and genetic pathways that maintain this redox balance, researchers are finding ways to make even the most resistant cancers vulnerable to treatment.
The Redox Paradox and the Antioxidant Shield
Cancer cells often exist in a state of elevated oxidative stress compared to healthy cells. To survive this, they hijack pathways to maintain a high basal antioxidant capacity. This creates a "redox paradox": while ROS can drive tumor progression by promoting mutations, malignant cells become dependent on a specific homeostasis set point. As Bin Liu and colleagues demonstrated in A reduction in reactive oxygen species contributes to dihydromyricetin-induced apoptosis in human hepatocellular carcinoma cells, disrupting this signaling—even by reducing ROS below a necessary threshold—can trigger mitochondrial suicide programs.
The primary component of this shield is glutathione (GSH), a potent antioxidant that scavenges ROS before they can do damage. In the tumor microenvironment, high GSH concentrations act as a biological buffer. As Wanlan TANG explains in pH Responsive Copper-Doped Mesoporous Silica Nanocatalyst for Enhanced Chemo-Chemodynamic Tumor Therapy, this buffer is so effective that it can neutralize the therapeutic impact of treatments designed to trigger oxidative stress, such as Chemodynamic Therapy (CDT).
Dismantling the Defense Infrastructure
To overcome this resistance, researchers are targeting the "factories" and "regulators" that produce these antioxidants.
Targeting Metabolic Pathways
Pancreatic cancer stem cells, for instance, rely on non-canonical glutamine metabolism to fuel their defenses. Doudou Li and Zhiqiang Fu showed that inhibiting the enzyme GOT1 floods these cells with ROS, stripping away their shield and making them significantly more sensitive to radiotherapy Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy.
Inhibiting Master Regulators
The protein NRF2 acts as a master switch for the antioxidant response. Tumors often over-activate NRF2 to resist chemotherapy. Dian Zhang identified that the enzyme USP35 stabilizes NRF2 in esophageal cancer; by targeting USP35, the protective response is weakened, restoring the efficacy of drugs like Cisplatin The deubiquitinating enzyme USP35 regulates the stability of NRF2 protein. Similarly, Wenhui Li discovered that a circular RNA, circNSD1, can shut down these pathways in breast cancer by interfering with autophagy receptors Circular RNA profiling and functional screening in breast cancer identify circNSD1(6) as a suppressor of tumor autophagy.
Triggering Ferroptosis: Death by Lipid Peroxidation
A particularly effective way to exploit a weakened antioxidant shield is by inducing ferroptosis—a form of iron-dependent, oxidative cell death characterized by the catastrophic collapse of cell membranes through lipid peroxidation.
Normally, enzymes like GPX4 prevent this collapse. However, by knocking down "shield" proteins like RRM1, researchers like BIN CHEN have successfully triggered ferroptosis in response to standard radiation and chemotherapy Knockdown of RRM1 in tumor cells promotes radio-/chemotherapy induced ferroptosis by regulating p53 ubiquitination and p21-GPX4 signaling axis. This approach is especially promising for eliminating "seeds" of cancer, such as leukemia stem cells, which Jie Zha found could be targeted by combining HDAC inhibitors and PPAR agonists to disrupt the SLC7A11 signaling axis Combinations of HDAC inhibitor and PPAR agonist induce ferroptosis of leukemia stem and progenitor cells in acute myeloid leukemia.
Engineering the "One-Two Punch" with Nanotechnology
The most advanced iterations of this research involve multifunctional nanoplatforms that act as both the weapon and the shield-breaker.
- ROS Generation: These platforms often use nanozymes—nanoparticles that mimic enzymes like peroxidase to trigger the Fenton reaction, converting endogenous hydrogen peroxide into toxic hydroxyl radicals Chi Deng, Iron-based nanozymes induced ferroptosis for tumor therapy.
- Antioxidant Depletion: Simultaneously, these particles are designed to deplete GSH. For example, the PyroFPSH platform developed by Letian Lv synchronizes photodynamic therapy with GSH stripping to ensure that the generated ROS reach the threshold of toxicity Enhanced photodynamic therapy through multienzyme-like MOF for cancer treatment.
- Environmental Tuning: Some platforms even modify the tumor's pH. Yang Peng developed "proton sponge" nanoparticles that capture excess protons, boosting local bicarbonate levels to supercharge manganese-mediated ROS generation by 1000-fold Proton nanomodulators for enhanced Mn2+-mediated chemodynamic therapy of tumors via HCO3− regulation.
Why This Matters
The intuition behind this research direction is a shift from simply "hitting harder" with more radiation or higher drug doses to "hitting smarter" by removing the tumor's ability to recover. By targeting the specific enzymes (like catalase in CML, as shown by Lili Song in Targeting Catalase but Not Peroxiredoxins Enhances Arsenic Trioxide-Induced Apoptosis in K562 Cells) and metabolic pathways that maintain the antioxidant shield, clinicians can restore the effectiveness of existing therapies and pave the way for highly selective, "green" treatments like chemodynamic therapy.